Non-Small Cell Lung Cancer (Nsclc) Market - Growth, Trends, Covid-19 Impact, and Forecasts (202(2023 - 2028)

Non-Small Cell Lung Cancer (Nsclc) Market - Growth, Trends, Covid-19 Impact, and Forecasts (202(2023 - 2028)

The Non-small Cell Lung Cancer (NSCLC) market is projected to register a CAGR of 9.5% during the forecast period (2022-2027).

Covid-19 significantly affected the non-small cell lung cancer-related clinical trials across the world. Several market players halted their clinical trials due to a financial crisis in the year. For instance, according to clinicaltrials.gov in July 2021, it was observed that more than 200 interventional studies were halted from March to April 2020 due to the emergence of COVID-19. Additionally, fluctuation in the market is mainly due to the disruption in the supply chain of raw materials and end products. Moreover, According to an article published in September 2020 titled "The impact of the COVID-19 pandemic on lung cancer patients," at the Fifth Affiliated Hospital of Sun Yat-sen University, around 95 patients out of 161 had delayed their return visit in April 2020, and 47 cases were finally designated as having delayed admission during the pandemic and having to discontinue or delay their regular anticancer treatments. However, cancer care and maintaining high standards of diagnosis and treatment have been the major priorities of the national healthcare bodies and international healthcare systems worldwide.

The growing number of patients suffering from non-small cell lung cancer across the world is one of the key drivers of the growth of the market. This is majorly due to the increasing number of people with unhealthy habits such as smoking, tobacco & alcohol consumption, high dose of supplements, and sedentary lifestyle across the world. Additionally, increasing pollution level in the air is also one of the major factors contributing to the increase in the number of patients. As per the statistics provided by the World Health Organization (WHO) updates from February 2022, 2.2 million patients were diagnosed with lung cancer in 2020, and non-small cell lung cancer accounted for nearly 85% of the share of all lung cancer patients. Thus, the availability of a large patient base and a further increasing number of non-small cell lung cancer patients resulted in the high demand for therapy to treat the patients.

Recent approvals of new drugs are expected to accelerate the market growth during the forecast period. In February 2022, the Medicines and Healthcare products Regulatory Agency (MHRA) approved Genentech’s Tecentriq to treat early-stage non-small cell lung cancer. Similarly, in October 2021, United States Food and Drug Administration (USFDA) approved atezolizumab (Tecentriq, Genentech, Inc.) in United States for stage II and IIIA non-small cell lung cancer patients. In March 2021, the FDA approved Pfizer’s Lorbrena (lorlatinib) to treat ALK-positive NSCLC patients in United States. Additionally, in October 2021, Ventana Medical Systems, Inc. received United States FDA approval for VENTANA PD-L1 (SP263) Assay as a companion diagnostic device to select patients for Tecentriq. Hence, recent new drug approvals and the launch of companion diagnostics to select targeted patients are responsible for the growth of the market during the forecast period.

Targeted therapy drugs are often used to treat advanced lung cancers and are either used along with chemotherapy or used individually. Some of the major targeted therapy drugs to treat non-small cell lung cancer are Erlotinib (Tarceva), Gefitinib (Iressa), Afatinib (Gilotrif), Mobocertinib (Exkivity), Osimertinib (Tagrisso), and Dacomitinib (Vizimpro). These drugs targets mutated genes in the body and thereby avoid adverse effect on healthy cells. Investment by market players for the development of targeted therapy due to its advantages over standard chemotherapy and entry of these drugs in multiple countries across the world are likely to drive the market growth.

Major genes affected during non-small cell lung cancer are the KRAS gene, EGFR gene, T790M, ALK gene, ROS1, BRAF gene, RET, and MET gene. Hence, targeted therapy targets these genes, avoid their proliferation and thereby helps to treat non-small cell lung cancer. Investment by industry players for R&D activities responsible for the development of new treatments to treat various mutations during non-small cell lung cancer. For instance, in May 2021, United States Food and Drug Administration approved Rybrevant (amivantamab-vmjw) first-line treatment for a specific type of genetic mutated non-small cell lung cancer in adult patients. Rybrevant is the first targeted therapy for patients with epidermal growth factor receptor (EGFR) exon 20 insertion mutations in United States. The same day Food and Drug Administration approved Guardant Health Inc.’s Guardant360 CDx, a companion diagnostic for Rybrevant. Hence, approval and launch of such targeted therapy and their companion diagnostics are expected to propel the market growth during the forecast period. A strong pipeline of targeted therapy for non-small cell lung cancer is also expected to boost the market during the forecast period.

Thus, the segment is anticipated to witness significant growth over the forecast period due to the abovementioned factors.

North America is contributing a higher share across the world, majorly due to the high contribution from United States. This can be majorly due to the local presence of major industry players, well-established healthcare infrastructure, and high diagnosis and treatment rates in the country.

Moreover, in May 2021, United States Food and Drug Administration approved Rybrevant (amivantamab-vmjw) as the first treatment for adult patients with non-small cell lung cancer whose tumors have specific types of genetic mutations: epidermal growth factor receptor (EGFR) exon 20 insertion mutations. from February 2022, about 236,740 new cases of lung cancer are expected to diagnose in United States in 2022. Thus, the increasing cases of lung cancer are expected to boost the growth of the studied market in the region.

Moreover, in May 2021, United States Food and Drug Administration approved Rybrevant (amivantamab-vmjw) as the first treatment for adult patients with non-small cell lung cancer whose tumors have specific types of genetic mutations: epidermal growth factor receptor (EGFR) exon 20 insertion mutations. Also, in May 2021, United States Food and Drug Administration approved Lumakras (sotorasib) as the first treatment for adult patients with non-small cell lung cancer whose tumors have a specific type of genetic mutation called KRAS G12C and who have received at least one prior systemic therapy.

Furtheremore, high research and development activities, the launch of companion diagnostics by industry players, and huge healthcare spending are fueling the growth of the overall regional market to a large extent. ​The cost of treatment which includes chemotherapy, immunotherapy, targeted therapy, radiation, and in some cases, surgery, is huge, and the availability of significant reimbursement in the region is likely to accelerate the market growth.

The non-small cell lung cancer market is fragmented and competitive and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. F. Hoffmann-La Roche, AstraZeneca, Bristol-Myers Squibb, Merck, Novartis, Pfizer, Takeda Pharmaceuticals, Bayer Healthcare, Eli Lilly and Company, and GlaxoSmithKline are some of the key companies dominating the global market.

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support